ClinicalTrials.gg
RecruitingNCT07564466Updated Oct 27, 2026

A Study of SKB571 in Participants With Gastrointestinal Tumors

A Phase 2 interventional study of SKB571 for injection in Gastrointestinal Tumors, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 26 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 27, 2026Site recruiting status changedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Digestive System Neoplasms with a site in China — 35 open to participants now, 40 under way, 4 of them phase 3. Digestive System Neoplasms · China.

Planned enrollment
19th of 64
160 · median 60
Started
2026
with 7 others
Phase 2
21 of 75
6 open now
Primary completion
2027-08
later than 22 of 39 live
Registered
70th of 75
by date

Among the 75 studies in Digestive System Neoplasms with a site in China, this one is the 19th largest by planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2026, is one of 21 in phase 2, reaches primary completion later than 22 of the 39 other live ones, and was the 70th registered.

Digestive System Neoplasms

195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.

Browse Digestive System Neoplasms studies →

Open to participants now

35 of the 75 studies in Digestive System Neoplasms with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Digestive System Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.

Read the detailed description

This is a multicenter, open-label, Phase II clinical study to evaluate the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with gastrointestinal tumors. Approximately 120 subjects will be enrolled in this study, including 4 cohorts with approximately 20-30 participants enrolled in each cohort.

03

Conditions studied

  • Gastrointestinal Tumors

Keywords

  • Gastrointestinal tumors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the form (ICF).
  2. Participants must have or cytologically confirmed gastrointestinal tumors.
  3. At least one as assessed by the investigator according to v1.1.
  4. (ECOG) performance status of 0 or 1.
  5. ≥ 12 weeks as assessed by the investigator.
  6. Adequate organ and bone marrow function.
  7. Male and female participants must agree to use highly effective methods of during the study treatment period.
  8. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with other malignant tumors within 3 years before the first dose of study treatment.
  2. History or current to central nervous system.
  3. Current uncontrolled concomitant diseases
  4. Clinically severe lung damage due to complications of lung disorder
  5. Participants with a history of interstitial lung disease (ILD)/non-infectious pneumonitis
  6. A history of severe skin diseases
  7. Unresolved toxicity from prior anti-tumor therapy
  8. Serious infection within 4 weeks before the first dose of study treatment
  9. Known active pulmonary tuberculosis.
  10. Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study.
  11. Known history of allogeneic organ transplant or hematopoietic stem cell transplant.
  12. Pregnant or breastfeeding women.
  13. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ)

    Drug: SKB571 for injection

  • Experimental
    Oesophageal Squamous Cell Carcinoma (ESCC)

    Drug: SKB571 for injection

  • Experimental
    Colorectal Adenocarcinoma (CRC)

    Drug: SKB571 for injection

  • Experimental
    Bile Duct Cancer (BTC)

    Drug: SKB571 for injection

  • Experimental
    Hepatocellular Carcinoma (HCC) or other types of gastrointestinal tumors

    Drug: SKB571 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and overall survival (OS)

    Time frame: Up to approximately 24 months

  2. Safety and tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (based on CTCAE v6.0), clinically significant abnormal laboratory test results, etc.

    Time frame: Up to approximately 24 months

  3. Maximum Plasma Concentration (Cmax) of SKB571-ADC

    Blood Samples will be collected to determine the Cmax of SKB571-ADC in the plasma

    Time frame: Up to approximately 24 months

  4. Immunogenicity

    Blood Samples will be collected to measure Anti-drug antibody (ADA) against SKB571 in the serum

    Time frame: Up to approximately 24 months

  5. Minimum Plasma Concentration(Cmin) of SKB571-ADC

    Blood samples will be collected to determine the Cmin of SKB571-ADC in the plasma

    Time frame: Up to approximately 24 months

  6. Maximum Plasma Concentration(Cmax) of SKB571-TAb

    Blood samples will be collected to determine the Cmax of SKB571-TAb in the plasma

    Time frame: Up to approximately 24 months

  7. Minimum Plasma Concentration(Cmin) of SKB571-TAb

    Blood Samples will be collected to determine the Cmin of SKB571-TAb in the plasma

    Time frame: Up to approximately 24 months

  8. Maximum Plasma Concentration (Cmax) of unconjugated KL610348

    Blood Samples will be collected to determine the Cmax of unconjugated KL610348 in the plasma

    Time frame: Up to approximately 24 months

  9. Minimum Plasma Concentration(Cmin) of unconjugated KL610348

    Blood Samples will be collected to determine the Cmin of unconjugated KL610348 in the plasma

    Time frame: Up to approximately 24 months

Other outcomes

  1. Correlation between biomarkers and efficacy

    To evaluate the correlation between the expression levels of tumor-related genes in tumor tissues and efficacy

    Time frame: Up to approximately 24 months

07

Study locations

25 of 26 sites recruiting
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing Municipality 404000, China
    Recruiting
    • Li Zhang · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Yigui Chen · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Recruiting
    • Jiayi Li · Principal investigator
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Ruihua Xu · Principal investigator
  • The Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510655, China
    Recruiting
    • Yanhong Deng · Principal investigator
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
    Recruiting
    • Yuhua Cao · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
    Recruiting
    • Jian Shi · Principal investigator
    • Fengbin Zhang · Principal investigator
  • Tumor Hospital of Harbin Medical University
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yanqiao Zhang · Principal investigator
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471003, China
    Recruiting
    • Jun Yao · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Yan Zhao · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Ruihua Zhao · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Zhenyang Liu · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Xia He · Principal investigator
    • Sheng Li · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Yanhong Gu · Principal investigator
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 3300029, China
    Recruiting
    • Huiqing Zhang · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Anwen Liu · Principal investigator
    • Hua Wang · Principal investigator
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
    • Wei Li · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Recruiting
    • Jinglei Qu · Principal investigator
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
    Recruiting
    • Hui Guo · Principal investigator
    • Xiaoran Guo · Principal investigator
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
    Recruiting
    • Lei Cong · Principal investigator
  • Cancer Hospital of Shandong First Medical University
    Jinan, Shandong 250117, China
    Recruiting
    • Changzheng Li · Principal investigator
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200127, China
    Recruiting
    • Xiuying Xiao · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Recruiting
    • Hongxia Lu · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610041, China
    Recruiting
    • Yongdong Jin · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Ting Deng · Principal investigator
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
    Not yet recruiting
    • Da Li · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Of 29 phase 2 interventional studies under Digestive System Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
May 4, 2026
StartActual
May 20, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • Fujian Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
  • The Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, ChinaNot yet recruiting→Recruiting
  • The Fourth Hospital of Hebei Medical University · Shijiazhuang, ChinaNot yet recruiting→Recruiting
  • Tumor Hospital of Harbin Medical University · Harbin, ChinaNot yet recruiting→Recruiting
  • Henan Cancer Hospital · Zhengzhou, ChinaNot yet recruiting→Recruiting
  • Jiangxi Cancer Hospital · Nanchang, ChinaNot yet recruiting→Recruiting
  • The Second Affiliated Hospital of Nanchang University · Nanchang, ChinaNot yet recruiting→Recruiting
  • The First Hospital of China Medical University · Shenyang, ChinaNot yet recruiting→Recruiting
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, ChinaNot yet recruiting→Recruiting
  • Shanxi Provincial Cancer Hospital · Taiyuan, ChinaNot yet recruiting→Recruiting
  • Sichuan Cancer Hospital · Chengdu, ChinaNot yet recruiting→Recruiting
Show site
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, China
Oct 27, 2026
Enrollment
120→160
Oct 27, 2026
Interventions
Arm changed Hepatocellular Carcinoma (HCC) or Bile Duct Cancer (BTC) or other types of gastrointestinal tumors→Hepatocellular Carcinoma (HCC) or other types of gastrointestinal tumors. Arms added: Bile Duct Cancer (BTC)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    1 site added. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • Fujian Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
    • The Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, ChinaNot yet recruiting→Recruiting
    • The Fourth Hospital of Hebei Medical University · Shijiazhuang, ChinaNot yet recruiting→Recruiting
    • Tumor Hospital of Harbin Medical University · Harbin, ChinaNot yet recruiting→Recruiting
    • Henan Cancer Hospital · Zhengzhou, ChinaNot yet recruiting→Recruiting
    • Jiangxi Cancer Hospital · Nanchang, ChinaNot yet recruiting→Recruiting
    • The Second Affiliated Hospital of Nanchang University · Nanchang, ChinaNot yet recruiting→Recruiting
    • The First Hospital of China Medical University · Shenyang, ChinaNot yet recruiting→Recruiting
    • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, ChinaNot yet recruiting→Recruiting
    • Shanxi Provincial Cancer Hospital · Taiyuan, ChinaNot yet recruiting→Recruiting
    • Sichuan Cancer Hospital · Chengdu, ChinaNot yet recruiting→Recruiting
    Show site
    • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, China
    Enrollment 120→160
    Interventions Arm changed Hepatocellular Carcinoma (HCC) or Bile Duct Cancer (BTC) or other types of gastrointestinal tumors→Hepatocellular Carcinoma (HCC) or other types of gastrointestinal tumors. Arms added: Bile Duct Cancer (BTC)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07564466
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 20, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Xin Li, MD
Contact
lixin@kelun.com
86-13311373861

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SKB571

Start the discussion